Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab combined with TP chemotherapy for perioperative penile cancer
ChiCTR2400094629Phase 4Recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, paclitaxel and cisplatin in penile cancer and penile squamous cell carcinoma (PSCC), sponsored by Tianjin First Central Hospital. Primary endpoints: Objective response rate and Progression-free survival. Started Aug 2023; status: recruiting.
02
Drugs
sintilimabpaclitaxelcisplatin
03
Conditions
penile cancerpenile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2400094629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094629.